Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paquinimod - Active Biotech

Next Previous
X
Search
Drug Profile

Paquinimod - Active Biotech

Alternative Names: 57-57; ABR-215757; SLE 57-57

Latest Information Update: 18 Feb 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Active Biotech
  • Class Amides; Anti-inflammatories; Quinolines; Skin disorder therapies; Small molecules
  • Mechanism of Action Calgranulin B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis; Systemic lupus erythematosus; Systemic scleroderma

Most Recent Events

  • 18 Feb 2021 Discontinued - Phase-II for Systemic scleroderma in Sweden, Germany, Switzerland (PO) (Active Biotech pipeline, February 2021)
  • 07 Dec 2018 Active Biotech plans a phase II trial for Systemic scleroderma
  • 06 Dec 2018 Active Biotech reactivates development of Paquinimod in Systemic scleroderma in Germany (PO) (Active Biotech pipeline, December 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top